at patient outcomes after >2 years of P treatment. The aim of this real-world study was to evaluate patient outcomes related to P use for >2 years in patients with stage IV NSCLC. Using the de-identified Precision Q database, authors evaluated
Search Results
Lucio Gordan, Rushir Choksi, Daniel Petro, Melissa Johnson, Anupama Vasudevan, Sandy English, Marielle Fares, Heidi Gidley, Teena Sura, and Prateesh Varughese
Ashley Schlafstein, Subir Goyal, Ashley Aiken, Jill Remick, Nabil Saba, James Bates, Soumon Rudra, Mark McDonald, Azeem Kaka, and William Stokes
Purpose/Objective(s): Analyses of national care patterns and outcomes among patients with T4 laryngeal squamous cell carcinoma (L-SCC) have demonstrated a concomitant increase in the use of larynx preservation (LP) and a decrease in overall
Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau
to the cancer center. Pembrolizumab ED has been evaluated through pharmacokinetic studies and simulated model-based analyses, however clinical data are lacking. The aim of this study is to evaluate real-world outcomes and safety of ED vs standard
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah
use in the real-world setting is scarce. Objective : To examine treatment patterns and outcomes among BRAF+ cutaneous melanoma patients treated with adjuvant IO or DT in the United States. Methods: This was a retrospective cohort study using
Udhayvir Singh Grewal, Subhash Chandra Garikipati, Parth Rajeshbhai Shah, Shiva Jashwanth Gaddam, Aakash Rajendra Sheth, and Ghanshyam Mudigonda
conducted the current analysis to study the impact of access to various specialties on the overall outcomes in CRC patients. Materials and Methods: The National Provider Identifier (NPI) database was interrogated to identify the number of gastroenterology
John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape
proliferation and necrosis. 1 Although histologic classification allowed patients with a single disease to be enrolled into clinical trials, and treatment protocols for these patients to be standardized, 2 outcomes were variable and could not be attributed to
Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le
—Symptom screening with Targeted Early Palliative care (STEP)—for patients with advanced cancer. Secondary aims were to assess whether STEP identified patients with worse QoL and other patient-reported outcomes (PROs), and whether screen-positive patients who
Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng
and associated outcomes (time to treatment discontinuation [TTD] and treatment adherence) in selpercatinib-treated US patients. Methods: This retrospective cohort study used de-identified data from two administrative real-world claims databases
Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins
equivalent for >4 weeks receive antimicrobial prophylaxis for Pneumocystis jirovecii pneumonia (PJP). Limited data exist regarding the incidence and outcome of OIs among patients receiving ICIs who need SS and/or ISAs for >4 weeks to manage irAEs
Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood
scan. Outcomes would be expected to differ significantly between these groups. Andre et al. 5 retrospectively analyzed data on 702 consecutive patients with N2 disease at 6 French centers and found that the degree of N2 involvement correlated with